Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Kotloff is Chairman of the Department of Pulmonary Medicine at the Cleveland Clinic. He has worked in the field of lung transplantation for the past 25 years and has extensive clinical experience in the evaluation of transplant candidates and in the care of transplant recipients. In addition to his involvement in lung transplantation, Dr. Kotloff has special expertise in the evaluation and management of patients with lymphangioleiomyomatosis (LAM) and other cystic lung diseases. He also maintains an active interest in general pulmonary medicine and, in particular, in evaluating patients with complex pulmonary disorders.
In addition to his clinical activities, Dr. Kotloff has made medical education and scholarship a focus of his career. He has authored over 100 peer-reviewed articles, reviews, and book chapters and has edited or co-edited six books. He previously directed the Pulmonary and Critical Care Fellowship Training Program at the University of Pennsylvania for 24 years. He has served as Chair of the Pulmonary Disease Test Writing Committee of the American Board of Internal Medicine, Chair of the Transplant Network of the American College of Chest Physicians, and as President of the Association of Pulmonary and Critical Care Medicine Program Directors. He was an Associate Editor of the American Journal of Respiratory and Critical Care Medicine from 2010-14 and is currently a Section Editor for CHEST and an Associate Editor of the Annals of the American Thoracic Society. He is the 2011 recipient of the American College of Chest Physicians College Medalist Award recognizing “meritorious service in furthering work in chest medicine.” He is also the 2016 recipient of the American Thoracic Society Outstanding Educator Award, which recognizes "lifetime contributions in education and mentoring in the fields of pulmonary, critical care or sleep medicine."
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 3/28/2016, Dr. Kotloff has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.